🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

PLATO ACT 4 results for dose de-escalation in early-stage anal cancer are out! Prof Sebag-Montefiore presents on the plenary stage at #ESTRO24 3-year locoregional failure 16.4% for standard dose IMRT vs 12.4% reduced dose IMRT Reduced dose IMRT is safe & effective! #radonc

Had a patient tell me that she named her cancer(s) - Timmy the tumour, Nancy the node, and Larry the lump. I hope the AJCC’s taking🗒️because the time is now for a big update📝

#ASCO25: In LA gallbladder CA, adding CRT to neoadjuvant chemo doubled OS (21.8 vs 10.1 mo, p=0.006) & ↑ R0 resection rates (52% vs 30%) vs chemo alone in Phase III trial (N=124). First RCT evidence favoring NACRT in this tough-to-treat disease #radonc 🔗 meetings.asco.org/abstracts-pres…

Dr. Nina Niu Sanford I’m having trouble enrolling to oligomet trials myself. When i discuss it with patients and offer randomization to aggressively targeting Oligometastatic disease versus doing nothing, patients tend to ask if we could take the aggressive approach outside of the trial. Even if the

Honored to present the results of POLCA GB Trial of neoadjuvant chemoradiation vs chemotherapy alone in borderline respectable Gall bladder cancers Oral presentation at ASCO 2025 on 31st May asco.org/abstracts-pres…

"All treatments are 'tolerable' ...if you don't ask people who they feel." Dr Dawn Hershman getting #ASCO25's highest honor, the @asco David Karnofsky Science of Oncology Award for fostering a new world of patient-centered research and care.

Dr Steven H. Lin of MD Anderson Cancer Center making a case for all-radiation-is-not-same-radiation in the context of organ preservation in oesophageal cancer and a brief look at where we are headed in this space #ASCO25.

Dr Reena Engineer from TMC Radiation Oncology presents results from Ph3 randomised POLCA-GB trial for LA Gall Bladder Ca #ASCO25 Addition of NACRT to NACT shows ✅Better response to Neoadjuvant Rx ✅Higher R0 resection rates ✅Higher EFS (4.9 Vs 10.6 mos) ✅Higher OS (10.1 Vs 21.8 mos)

Honored to share highlights of Reena Engineer’s presentation of POLCAGB phase III trial at #ASCO2025, a game changer for locally advanced gallbladder cancer Neoadj CRT vs CT alone: 🌟 Nearly doubled mOS (21.8 vs 10.1 months) 🌟 Significantly improved R0 resection (51.6% vs 29.7%)

Such a well deserved standing ovation for Chris Booth and the Challenge trial. These data are quite powerful. Much stronger evidence than what we saw in plenaries today. #ASCO25

🚨ESOPEC, Patterns of Recurrence🚨 🔥DM is the predominant pattern of recurrence and a large driver of mortality (~30-50%) ⚠️Locoregional Recurrence Remains notable (~20%) 🧐 Wonder about combined (Chemo + CRT) 🧨 to build on D-FLOT or FLOT, ❓ with organ preservation #ASCO25

Paolo Tarantino This is NOT true as the major driving risk factor for lymphedema is NOT nodal radiation it is Axillary surgery. As clinicians we need to be aware of lymphedema data first and second the shortcomings of B51 while counseling the patients.

🚨Study activated! NRG GI-011: Ph 3 RCT of Dose-Escalated RT in Locally Advanced Pancreas Cancer (LAP100) Here's a short (7 min) video. Please consider enrolling & reach out w any q's. Thanks to the NIH, NCI, NRG Oncology for supporting our work! clinicaltrials.gov/study/NCT06958… 🙏🙏🙏

We report one of the largest series of signet ring cell carcinoma of the ampulla of Vater, post resection. 🔑Presence of signet cells did not impact survival. 🧬 Rare histology, important insight! 🔗 doi.org/10.1007/s00423… Kunal Nandy Dr.Vikram Chaudhari Shailesh V. Shrikhande

Before you see the patient, you spent time and looked up. You know where he lives and who he lives with. Then don't ask "Where do you live?" or "Who do you live with?" Say, "I saw you live 30min away" or "I saw you live alone". 1/

Daniel Chang UMich Rad Onc Wow. That is pretty amazing! I love mine but you may have me beat!

PRIDE study proton RCT in adults with primary brain tumors (NCT06831461) is now live with the accrual of the first patient ACTREC-TMC Tata Memorial Hospital TMC Radiation Oncology The Particle Therapy Co-Operative Group (PTCOG) researchsquare.com/article/rs-680…

So thankful Dr David Palma, MD, PhD chose to rejoin X. This is a great story and an interesting walk through time.

Luna, a 9-year-old Husky, was paraplegic from a spinal tumor. After receiving SRT (20.01 Gy in 3 fx), she responded well and can walk again. Although Luna is still receiving chemo, she continues to do well. Learn more about RT for pet cancer ➡️ bit.ly/46oIlIt 🐾

"Many lives are lost not because they don't have access to newest technology or drugs, but because they didn't receive proven treatments in time" Bishal Gyawali, MD, PhD, FASCO wonderful to meet you ANZUP #anzup25 #CommonSenseOncology